 | Cas No. 956460-96-1, Capivasertib intermediate | Capivasertib | View detail » | |
![Cas No. 3680-69-1, 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine](//imrorwxhnlprli5q.ldycdn.com/cloud/ljBpqKkrllSRpjomqionip/3680-60-60.gif) | Cas No. 3680-69-1, 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine | Ruxolitinib, Tofacitinib, Ritlecitinib, Baricitinib, Abrocitinib, Delgocitinib | View detail » | 2016 |
 | Cas No. 252720-31-3, Capivasertib intermediate | Capivasertib | View detail » | |
 | Cas No. 886061-26-3, Capivasertib intermediate | Capivasertib | View detail » | |
![Cas No. 941685-27-4, 4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine](//imrorwxhnlprli5q.ldycdn.com/cloud/lpBpqKkrllSRpjommiqpip/941685-60-60.gif) | Cas No. 941685-27-4, Ruxolitinib intermediate | Ruxolitinib, Baricitinib | View detail » | 2017 |
![CAS No. 1375541-21-1, (S)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylicacid;(3'S)-1',2',5,7-Tetrahydro-2'-oxospiro[6H-cyclopenta[b]pyridine-6,3'-[3H]](//imrorwxhnlprli5q.ldycdn.com/cloud/jmBpqKkrllSRikmplnlmiq/1375541-60-60.gif) | CAS No. 1375541-21-1, Ubrogepant intermediate | Ubrogepant | View detail » | 2021 |
![Cas No. 1620056-83-8, 1H-Cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-1-acetic acid, 5,5-difluoro-3b,4,4a,5-tetrahydro-3-(trifluoromethyl)-, (3bS,4aR)-](//imrorwxhnlprli5q.ldycdn.com/cloud/jmBpqKkrllSRikiijlonin/1620056-60-60.gif) | Cas No. 1620056-83-8, Lenacapavir intermediate | Lenacapavir | View detail » | |
![Cas No. 2189684-54-4, Carbamic acid,N-[(1S)-1-[3-bromo-6-[3-methyl-3-(methylsulfonyl)-1-butyn-1-yl]-2-pyridinyl]-2-(3,5-difluorophenyl)ethyl]-,1,1-dimethylethyl ester](//imrorwxhnlprli5q.ldycdn.com/cloud/jjBpqKkrllSRikiijlmnio/2189684-60-60.gif) | Cas No. 2189684-54-4, Lenacapavir intermediate | Lenacapavir | View detail » | |
 | CAS No. 2375020-19-0, Lenacapavir Intermediate | Lenacapavir | View detail » | 2024 |
 | CAS No. 2375020-20-3, Lenacapavir Intermediate | Lenacapavir | View detail » | 2024 |
![CAS No. 2375019-85-3, 2-Pyridinemethanamine, 3-bromo-α-[(3,5-difluorophenyl)methyl]-6-[3-methyl-3-(methylsulfonyl)-1-butyn-1-yl]-, (αS)-](//imrorwxhnlprli5q.ldycdn.com/cloud/jpBpqKkrllSRiknpokjlio/2375019-60-60.gif) | CAS No. 2375019-85-3, Lenacapavir intermediate | Lenacapavir | View detail » | |
 | Cas No. 2189684-53-3, Lenacapavir intermediate | Lenacapavir | View detail » | |
![Cas No. 1620056-47-4, Carbamic acid, N-[(1S)-1-(3,6-dibromo-2-pyridinyl)-2-(3,5-difluorophenyl)ethyl]-, 1,1-dimethylethyl ester](//imrorwxhnlprli5q.ldycdn.com/cloud/jpBpqKkrllSRikiijlnnin/1620056-60-60.gif) | Cas No. 1620056-47-4, Lenacapavir intermediate | Lenacapavir | View detail » | |
 | Cas No. 2109226-54-0, Lenacapavir intermediate | Lenacapavir | View detail » | |
 | Fmoc-His-Aib-OH TFA, CAS No. 1446013-08-6, Semaglutide Intermediate | Semaglutide | View detail » | |
 | CAS No. 932710-63-9, aMphos | | View detail » | 2024 |
 | CAS No. 2821797-33-3 | | View detail » | |
 | CAS No. 722520-42-5, Elacestrant Intermediate | Elacestrant | View detail » | 2023 |
 | CAS No. 722520-36-7, Elacestrant Intermediate | Elacestrant | View detail » | 2022 |
 | CAS No. 2477812-39-6, Elacestrant Intermediate | Elacestrant | View detail » | |